EA201790091A1 - Лечение тяжелой гипертриглицеридемии - Google Patents

Лечение тяжелой гипертриглицеридемии

Info

Publication number
EA201790091A1
EA201790091A1 EA201790091A EA201790091A EA201790091A1 EA 201790091 A1 EA201790091 A1 EA 201790091A1 EA 201790091 A EA201790091 A EA 201790091A EA 201790091 A EA201790091 A EA 201790091A EA 201790091 A1 EA201790091 A1 EA 201790091A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
hypertrigliceridemia
heavy
mbh
type
Prior art date
Application number
EA201790091A
Other languages
English (en)
Inventor
Пол Баудес
Юнь-Цзюн Чой
Роберт Л. Мартин
Чарльз А. Макуэртер
Original Assignee
Саймабэй Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Саймабэй Терапьютикс, Инк. filed Critical Саймабэй Терапьютикс, Инк.
Publication of EA201790091A1 publication Critical patent/EA201790091A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Лечение тяжелой гипертриглицеридемии, такой как гиперлипопротеинемия типа I или типа V, с помощью терапии с использованием МВХ-8025 или соли МВХ-8025, отдельно или в комбинации с одним или более агентов, выбираемых из фибрата, ниацина и омега-3 жирной кислоты; необязательно сопровождаемой аферезом.
EA201790091A 2014-06-26 2015-06-25 Лечение тяжелой гипертриглицеридемии EA201790091A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462017444P 2014-06-26 2014-06-26
PCT/US2015/037596 WO2015200580A1 (en) 2014-06-26 2015-06-25 Treatment of severe hypertriglyceridemia

Publications (1)

Publication Number Publication Date
EA201790091A1 true EA201790091A1 (ru) 2017-07-31

Family

ID=53511030

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201790091A EA201790091A1 (ru) 2014-06-26 2015-06-25 Лечение тяжелой гипертриглицеридемии

Country Status (16)

Country Link
US (1) US20150374649A1 (ru)
EP (1) EP3160458A1 (ru)
JP (1) JP2017519028A (ru)
KR (1) KR20170020514A (ru)
CN (1) CN106470675A (ru)
AU (1) AU2015279905A1 (ru)
BR (1) BR112016028918A2 (ru)
CA (1) CA2951280A1 (ru)
CL (1) CL2016003290A1 (ru)
EA (1) EA201790091A1 (ru)
HK (1) HK1231380A1 (ru)
IL (1) IL249757A0 (ru)
MX (1) MX2016017081A (ru)
PH (1) PH12016502415A1 (ru)
SG (1) SG11201610243YA (ru)
WO (1) WO2015200580A1 (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
SI3119384T1 (sl) 2014-03-20 2018-12-31 Cymabay Therapeutics, Inc. Zdravljenje intrahepatičnih holestatičnih bolezni
KR102374499B1 (ko) 2014-04-11 2022-03-14 사이머베이 쎄라퓨틱스, 인코퍼레이티드 Nafld 및 nash 의 치료
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
CN111741753A (zh) * 2017-12-21 2020-10-02 兴和株式会社 治疗高甘油三酯血症的方法
WO2021097034A1 (en) 2019-11-14 2021-05-20 Cymabay Therapeutics, Inc. Seladelpar for use in the treatment of intestinal barrier dysfunction and associated diseases
WO2021097027A1 (en) 2019-11-14 2021-05-20 Cymabay Therapeutics, Inc. Seladelpar for use in the treatment of alcoholic liver disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7301050B2 (en) 2003-09-19 2007-11-27 Janssen Pharmaceutical N.V. 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
JO3006B1 (ar) * 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
JP2013523746A (ja) * 2010-03-30 2013-06-17 ノバルティス アーゲー Ｄｇａｔ１阻害剤の使用

Also Published As

Publication number Publication date
MX2016017081A (es) 2017-05-01
CN106470675A (zh) 2017-03-01
AU2015279905A1 (en) 2017-02-02
WO2015200580A1 (en) 2015-12-30
KR20170020514A (ko) 2017-02-22
BR112016028918A2 (pt) 2017-08-22
HK1231380A1 (zh) 2017-12-22
IL249757A0 (en) 2017-02-28
US20150374649A1 (en) 2015-12-31
PH12016502415A1 (en) 2017-02-27
CL2016003290A1 (es) 2017-09-08
JP2017519028A (ja) 2017-07-13
EP3160458A1 (en) 2017-05-03
SG11201610243YA (en) 2017-01-27
CA2951280A1 (en) 2015-12-30

Similar Documents

Publication Publication Date Title
EA201790091A1 (ru) Лечение тяжелой гипертриглицеридемии
EA201790737A1 (ru) Комбинированная терапия
EA201790649A1 (ru) Бензилзамещенные индазолы в качестве ингибиторов bub 1
EA201691582A1 (ru) Новые фармацевтические препараты
EA201790273A1 (ru) Флагеллиновые композиции и их применение
MA41028A (fr) Méthodes et formulations pour le traitement de pathologies oculaires vasculaires
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
DE102015009910A8 (de) Automatische Aggregation von Online-Benutzerprofilen
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
EA201691610A8 (ru) Анти-jagged1 антитела и способы применения
EA201790785A1 (ru) Производные тетрагидроизохинолина
DK3229840T3 (da) 3,5-dihydroxy-4-isopropyl-trans-stilben til anvendelse i topisk behandling af akne
EA201692529A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
EA201600589A1 (ru) Ингибиторы диацилглицеринацилтрансферазы 2 для применения в лечении метаболических и связанных с метаболизмом расстройств
EA201890810A1 (ru) Соединения, эффективные для лечения гепатотоксичности и стеатоза печени, и их применение
EA201791467A1 (ru) Водный офтальмологический раствор
CU24407B1 (es) Moduladores de pirrolopiridina de rorc2 sustituidos con metilo y trifluorometilo
EA201890776A1 (ru) Агонисты ppar, соединения, фармацевтические композиции и способы их применения
MX2017006015A (es) Composiciones para usar en el tratamiento de cancer renal.
EA201792096A3 (ru) РАППγ АГОНИСТЫ ДЛЯ ЛЕЧЕНИЯ РАССЕЯННОГО СКЛЕРОЗА
EA201691887A1 (ru) Лечение внутрипеченочных холестатических заболеваний
EA201791945A1 (ru) Пирролидинкарбоксамидопроизводные и способы их получения и их применение
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
BR112016027455A2 (pt) moduladores ppar
EA201791099A1 (ru) Хинолин карбоксамиды для применения в лечении лейкоза